A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors - Wikidata - wikimedia - TriplyDB

A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors

A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors

http://www.wikidata.org/entity/Q33435808

about

The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors.

P2860

Q28070264-1C0A8245-A003-40DF-B5C1-C21473CAD2E0 Q47118215-2664F4A1-1F4D-418E-831A-36C5D2D25C94

P2860

A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors

http://www.wikidata.org/entity/Q33435808

description

2016 nî lūn-bûn

@nan

2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors

@ast

A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors

@en

type

label

A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors

@ast

A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors

@en

prefLabel

A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors

@ast

A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors

@en

P1433

Q33435808-65AE96D9-9DB1-45E7-8CA6-0F5F6173600E

P1476

Q33435808-2315E76C-E11C-4F64-9092-4B882CBECD8A

P2093

Q33435808-134C28A5-EC53-4463-A931-DF66C2143B62

Q33435808-1DD4DEF2-2F5A-4A24-A1E7-1205B71BAB35

Q33435808-759168CA-1272-4A53-8E45-7F24FE4E245A

Q33435808-82DA2222-CA26-4B62-82E3-18115C5043E9

Q33435808-8757CF80-75FF-4435-B7FE-A40B20D9CAAA

Q33435808-8D7018A2-0DA7-4365-9E69-F47BDEE7CB23

Q33435808-923672DB-5E27-4F9F-81CD-E5666F9C54CD

Q33435808-A771ED26-4784-44FD-ABB1-57B66CF6B1DD

Q33435808-CE7DF07A-CCF0-472D-8D98-C5A92BF06010

Q33435808-D2D02783-BF71-4F1B-937E-E5277148CBD1

P2860

Q33435808-00C2B256-E8E8-4319-9AD6-B9B3FB5A35D8

Q33435808-054C2083-0F0E-4CF1-8D2A-BE6FCA78C3A6

Q33435808-0A945869-82EA-4A49-B1AA-87013007ADE1

Q33435808-0CA65980-2C86-4EAA-9D17-52804F18BC24

Q33435808-0E81DA65-C4F1-42F0-8EBA-7C0D2DD08890

Q33435808-1D93150E-12C5-49BA-8F76-88116544CCED

Q33435808-2C789CC8-1AFF-4BB2-96CD-73A62E89AF8F

Q33435808-352F93FB-3D38-4B4C-9A61-82E8D7918993

Q33435808-36F1AE70-8C49-43D1-AB35-EF28DA56A749

Q33435808-508E50E5-4AB7-43DD-82B8-EEBD5041356F

P304

Q33435808-6B47D499-78F2-46BE-8C98-4F65FE415461

P31

Q33435808-F697E4B7-8271-4EE0-8564-587F47B77688

P356

Q33435808-8FB58E78-121F-4A35-99A5-B990E94C315E

P407

Q33435808-49A76725-9043-483D-9629-BB05F763A884

P433

Q33435808-33E9E8EC-EF4E-40F8-B5B2-E238E5BC168C

P478

Q33435808-AAF94F72-C78A-4C36-8CBB-7F146025B894

P50

Q33435808-087CA41C-C0EC-4CBB-927B-AD505F049207

P577

Q33435808-808D99B7-1723-4453-B3A7-2872CBEF7039

P698

Q33435808-D4E46AD8-1A01-4A23-8DA5-C5B35F126E43

P932

Q33435808-155646BF-0929-4F9E-A6E7-7E72B2BBD2B0

P356

ONCOTARGET.12450

P1433

P1476

A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors

@en

P2093

Andrew D J Pearson

http://www.w3.org/2001/XMLSchema#string

Birgit Geoerger

http://www.w3.org/2001/XMLSchema#string

Frank G Haluska

http://www.w3.org/2001/XMLSchema#string

Isabelle Aerts

http://www.w3.org/2001/XMLSchema#string

Robert Iannone

http://www.w3.org/2001/XMLSchema#string

Ruixue Wang

http://www.w3.org/2001/XMLSchema#string

Ryan D Geschwindt

http://www.w3.org/2001/XMLSchema#string

Sara M Federico

http://www.w3.org/2001/XMLSchema#string

Steven G DuBois

http://www.w3.org/2001/XMLSchema#string

Tanya M Trippett

http://www.w3.org/2001/XMLSchema#string

P2860

CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling

Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies

TOR signaling in growth and metabolism

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Ras, PI(3)K and mTOR signalling controls tumour cell growth

Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma

A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors.

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.

P304

84736-84747

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.12450

http://www.w3.org/2001/XMLSchema#string

P407

P433

51

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Darren Hargrave

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27713169

http://www.w3.org/2001/XMLSchema#string

P932

5356695

http://www.w3.org/2001/XMLSchema#string